INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 9 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.6%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PenderFund Capital Management Ltd. | 11,795,000 | $13,303 | 4.18% |
| Context Capital Management, LLC | 20,230 | $16,727 | 1.40% |
| OAKTREE CAPITAL MANAGEMENT LP | 8,816,000 | $7,289,292 | 0.08% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $187,043 | 0.04% |
| Calamos Advisors LLC | 5,000,000 | $4,156,550 | 0.02% |
| FRANKLIN RESOURCES INC | 21,000,000 | $17,363,331 | 0.01% |
| Russell Investments Group, Ltd. | 1,785,000 | $1,497,379 | 0.00% |
| UBS ASSET MANAGEMENT AMERICAS LLC | 3,000,000 | $2,481,591 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
This page lists INTERCEPT PHARMACEUTICALS IN's shareholders in Q1 2023. To view INTERCEPT PHARMACEUTICALS IN's shareholder history, click here.